JP2022551757A5 - - Google Patents

Info

Publication number
JP2022551757A5
JP2022551757A5 JP2022522653A JP2022522653A JP2022551757A5 JP 2022551757 A5 JP2022551757 A5 JP 2022551757A5 JP 2022522653 A JP2022522653 A JP 2022522653A JP 2022522653 A JP2022522653 A JP 2022522653A JP 2022551757 A5 JP2022551757 A5 JP 2022551757A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
antigen
cdr2
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022522653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551757A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/055480 external-priority patent/WO2021076554A1/en
Publication of JP2022551757A publication Critical patent/JP2022551757A/ja
Publication of JP2022551757A5 publication Critical patent/JP2022551757A5/ja
Ceased legal-status Critical Current

Links

JP2022522653A 2019-10-15 2020-10-14 Ｆｌｔ３を標的とする抗体およびその使用 Ceased JP2022551757A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962915120P 2019-10-15 2019-10-15
US62/915,120 2019-10-15
PCT/US2020/055480 WO2021076554A1 (en) 2019-10-15 2020-10-14 Antibodies targeting flt3 and use thereof

Publications (2)

Publication Number Publication Date
JP2022551757A JP2022551757A (ja) 2022-12-13
JP2022551757A5 true JP2022551757A5 (enExample) 2023-10-19

Family

ID=75538063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022522653A Ceased JP2022551757A (ja) 2019-10-15 2020-10-14 Ｆｌｔ３を標的とする抗体およびその使用

Country Status (16)

Country Link
US (1) US20240228628A9 (enExample)
EP (1) EP4045537A4 (enExample)
JP (1) JP2022551757A (enExample)
KR (1) KR20220082882A (enExample)
CN (1) CN115348972A (enExample)
AR (1) AR120222A1 (enExample)
AU (1) AU2020366000A1 (enExample)
BR (1) BR112022006817A2 (enExample)
CA (1) CA3153801A1 (enExample)
CL (1) CL2022000927A1 (enExample)
CO (1) CO2022004743A2 (enExample)
IL (1) IL292259A (enExample)
MX (1) MX2022004291A (enExample)
PE (1) PE20221256A1 (enExample)
TW (1) TWI867066B (enExample)
WO (1) WO2021076554A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020015994A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
CA3237846A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
KR102835308B1 (ko) 2018-08-08 2025-07-21 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
EP4291233A4 (en) * 2021-02-10 2025-05-21 Wugen, Inc. POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF DISEASES
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
AU2022330106A1 (en) * 2021-08-16 2024-03-21 Hemogenyx Pharmaceuticals Llc Anti-flt3 antibodies, cars, car t cells and methods of use
WO2023105087A1 (en) * 2021-12-10 2023-06-15 Tubulis Gmbh Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071891A1 (es) * 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
NL2014108B1 (en) * 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
EP3268038B1 (en) * 2015-03-09 2021-05-05 Agensys, Inc. Antibody drug conjugates (adc) that bind to flt3 proteins
WO2017011803A1 (en) * 2015-07-16 2017-01-19 Cellerant Therapeutics, Inc. Cysteine-substituted immunoglobulins
MY201312A (en) * 2017-06-02 2024-02-16 Pfizer Antibodies specific for flt3 and their uses
SG10202108528QA (en) * 2017-06-02 2021-09-29 Pfizer Chimeric antigen receptors targeting flt3
WO2019023097A1 (en) * 2017-07-26 2019-01-31 Smet Pharmaceutical Inc ASYMMETRIC BISPECIFIC ANTIBODIES AND THEIR USE
TW201930344A (zh) * 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法

Similar Documents

Publication Publication Date Title
JP2022551757A5 (enExample)
US11591401B2 (en) Anti-CD28 compositions
JP2024537772A5 (enExample)
IL311600A (en) Antibodies targeting BAFF-R and their use
JP2023524997A5 (enExample)
IL317912A (en) A combined chimeric antigen receptor targeting CD19 and CD20 and its applications
JP2021526844A5 (enExample)
JP7854121B2 (ja) 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法
US20230383012A1 (en) Antibodies that bind pd-l1, pd-l2, and/or cd28
JP2023525778A5 (enExample)
US20210277121A1 (en) Dual targeting antigen binding molecule
TW202221015A (zh) 單一及雙靶定配體誘導之t細胞銜接體組合物
JP2024504162A5 (enExample)
JP2019537449A5 (enExample)
US20250043001A1 (en) Anti-cd28 compositions
JP2021524451A (ja) 最適化済みｇｐ４１結合分子及びその使用
JP2024541476A5 (enExample)
JP2024516748A5 (enExample)
US20250084186A1 (en) Anti-cd28 x anti-enpp3 antibodies
JP2023554467A5 (enExample)
JP2025505933A5 (enExample)
CN116547306A (zh) 抗cd28和/或抗b7h3组合物
HK40073541A (en) Miniature guidance and navigation control (minignc) antibody-like proteins and methods of making and using thereof
TH2001000191A (th) โมเลกุลโพลีเปปไทด์ความจำเพาะคู่ที่ปรับปรุง